Stokes Family Office LLC Invests $228,000 in McKesson Co. (NYSE:MCK)

Stokes Family Office LLC purchased a new position in McKesson Co. (NYSE:MCK - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 400 shares of the company's stock, valued at approximately $228,000.

A number of other institutional investors have also made changes to their positions in the stock. Cibc World Market Inc. increased its stake in McKesson by 6.3% in the fourth quarter. Cibc World Market Inc. now owns 20,252 shares of the company's stock valued at $11,542,000 after purchasing an additional 1,207 shares in the last quarter. Commerce Bank increased its position in shares of McKesson by 2.0% in the 3rd quarter. Commerce Bank now owns 156,781 shares of the company's stock valued at $77,516,000 after buying an additional 3,020 shares in the last quarter. West Oak Capital LLC raised its stake in McKesson by 867.7% during the 4th quarter. West Oak Capital LLC now owns 3,000 shares of the company's stock worth $1,710,000 after buying an additional 2,690 shares during the period. Brentview Investment Management LLC bought a new position in McKesson during the fourth quarter worth about $3,018,000. Finally, Ingalls & Snyder LLC grew its stake in McKesson by 8.2% in the fourth quarter. Ingalls & Snyder LLC now owns 13,824 shares of the company's stock valued at $7,878,000 after acquiring an additional 1,047 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at McKesson

In related news, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $600.66, for a total value of $5,382,514.26. Following the transaction, the chief executive officer now owns 69,625 shares in the company, valued at approximately $41,820,952.50. This represents a 11.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Leann B. Smith sold 579 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total transaction of $331,645.41. Following the completion of the transaction, the executive vice president now directly owns 864 shares in the company, valued at approximately $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,689 shares of company stock worth $11,187,351. 0.11% of the stock is owned by company insiders.

Remove Ads

McKesson Stock Up 0.1 %

Shares of NYSE:MCK traded up $0.39 during midday trading on Monday, hitting $661.56. The stock had a trading volume of 775,431 shares, compared to its average volume of 800,762. The business's 50-day simple moving average is $616.14 and its 200-day simple moving average is $574.35. McKesson Co. has a 12 month low of $464.42 and a 12 month high of $673.23. The company has a market cap of $82.91 billion, a P/E ratio of 30.29, a PEG ratio of 1.29 and a beta of 0.52.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. As a group, equities analysts predict that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be given a $0.71 dividend. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.43%. McKesson's payout ratio is 13.00%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Mizuho started coverage on McKesson in a report on Wednesday, December 4th. They set a "neutral" rating and a $630.00 price objective on the stock. Evercore ISI upped their price target on shares of McKesson from $650.00 to $675.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Morgan Stanley raised their price objective on shares of McKesson from $612.00 to $642.00 and gave the stock an "overweight" rating in a report on Tuesday, December 17th. StockNews.com lowered shares of McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Finally, Wells Fargo & Company lifted their price target on McKesson from $641.00 to $691.00 and gave the company an "equal weight" rating in a research note on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $649.36.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.